| Multiple | Now | Sector median | Where it sits |
|---|---|---|---|
| P/E | 33.9× | −0.3× | |
| Price / Book | 4.0× | 2.5× | |
| Price / Sales | 2.4× | 3.5× | |
| Price / Free cash flow | 17.7× | 4.2× | |
| EV / EBITDA | 11.6× | 6.8× | |
| Earnings yield | 2.9% | −0.7% | |
| Free cash flow yield | 5.6% | 0.6% |
| Company | Price | Change | Mkt cap (USD) | P/E | ROE | 1Y |
|---|---|---|---|---|---|---|
0QLSE:0QCV.LAbbVie Inc. · 🌐 LSE | — | — | — | 111.2× | −129.2% | — |
0QLSE:0QAH.LMerck & Co., Inc. · 🌐 LSE | — | — | — | 20.5× | 34.7% | — |
0QLSE:0QQ6.LRoche Holding AG · 🌐 LSE | — | — | — | 23.2× | 38.1% | — |
AZLSE:AZN.LAstraZeneca PLC · 🌐 LSE | £125.36 | +1.10% | $259.81B | 25.1× | 21.0% | −1.3% |
0RLSE:0R0H.LThermo Fisher Scientific Inc. · 🌐 LSE | — | — | — | 34.0× | 12.6% | — |
0RLSE:0R2B.LDanaher Corporation · 🌐 LSE | — | — | — | 41.6× | 6.9% | — |
0RLSE:0R29.LIntuitive Surgical, Inc. · 🌐 LSE | — | — | — | 50.4× | 16.0% | — |
0QLSE:0QZU.LVertex Pharmaceuticals Incorporated · 🌐 LSE | — | — | — | 35.5× | 21.2% | — |
0RLSE:0R1F.LBristol-Myers Squibb Company · 🌐 LSE | — | — | — | 16.5× | 27.3% | — |
0RLSE:0R2S.LStryker Corporation · 🌐 LSE | — | — | — | 40.6× | 14.5% | — |
